Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bio-Techne (TECH) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Bio-Techne (TECH) over the last 17 years, with Q4 2025 value amounting to 13.54%.

  • Bio-Techne's EBITDA Margin rose 104000.0% to 13.54% in Q4 2025 from the same period last year, while for Dec 2025 it was 8.59%, marking a year-over-year decrease of 27900.0%. This contributed to the annual value of 7.53% for FY2025, which is 59200.0% down from last year.
  • Per Bio-Techne's latest filing, its EBITDA Margin stood at 13.54% for Q4 2025, which was up 104000.0% from 11.75% recorded in Q3 2025.
  • In the past 5 years, Bio-Techne's EBITDA Margin registered a high of 3647.25% during Q3 2022, and its lowest value of 1.42% during Q2 2025.
  • In the last 5 years, Bio-Techne's EBITDA Margin had a median value of 14.86% in 2022 and averaged 197.69%.
  • Per our database at Business Quant, Bio-Techne's EBITDA Margin skyrocketed by 36229300bps in 2022 and then tumbled by -36331500bps in 2023.
  • Over the past 5 years, Bio-Techne's EBITDA Margin (Quarter) stood at 31.53% in 2021, then decreased by -22bps to 24.56% in 2022, then tumbled by -38bps to 15.34% in 2023, then crashed by -80bps to 3.14% in 2024, then surged by 331bps to 13.54% in 2025.
  • Its EBITDA Margin stands at 13.54% for Q4 2025, versus 11.75% for Q3 2025 and 1.42% for Q2 2025.